Fig. 2From: Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal stem cell in patients with subacute complete spinal cord injury: safety considerations and possible outcomesPre- and post-injection MRIs of patients with numbers 1, 6, and 8. A Patient number 1, pre-injection. B Patient number 1, 6-month post-injection. C Patient number 6, pre-injection. D Patient number 6, 6-month post-injection. E Patient number 8, pre-injection. F Patient number 8, 6-month post-injectionBack to article page